PFE · Earnings call · 2026Q3T · Full report

Acquisition / Partnership / Divestiture

PFIZER INC · 2026-11-03 · Importance 46 · Surprise 42

Management said Pfizer’s business-development focus is on bolt-on acquisitions that complement its portfolio in four therapeutic areas, rather than prioritizing another large transaction. It cited approximately $6 billion of current business-development capacity following the Innovent transaction, which closed in the third quarter of 2026. Management said prospective deals should be strategically aligned, build on Pfizer’s expertise, and provide appropriate financial returns; it also pointed to ongoing commercial and R&D execution opportunities from Seagen and Metsera.

Key facts

• Pfizer has invested close to $80 billion in transactions over the last few years; about 80% was for Seagen, Metsera, and Biohaven.
• Pfizer's Q3 2026 adjusted diluted EPS of $0.87 included a $0.10 charge related to the Innovent transaction.
• Pfizer has an ongoing clinical trial with Relay using RLY-2608 in combination with atermaciclib.